Related Experiment Video

Updated: Jun 23, 2026

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

Circulating IL-8 levels in heart failure patients with and without metabolic syndrome

Min-Jeong Shin1, Kyung Hye Lee, Ji Hyung Chung

  • 1Department of Food and Nutrition, Korea University, Seoul, Republic of Korea.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|May 5, 2009
PubMed

Insights

Metabolic syndrome (MetS) in heart failure (HF) patients is linked to higher inflammation markers, including hsCRP and IL-8. This suggests inflammation plays a role in the relationship between MetS and HF progression.

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Inflammation Research

Background:

  • Metabolic syndrome (MetS) is suspected to increase heart failure (HF) risk and progression.
  • Mechanisms linking MetS and HF progression remain largely unknown.
  • This study investigates the association between MetS and inflammatory state in HF patients.

Purpose of the Study:

  • To determine if MetS presence correlates with an elevated inflammatory state in patients with heart failure.
  • To explore the relationship between metabolic syndrome and specific inflammatory markers in HF.

Main Methods:

  • Cross-sectional study of 91 stable heart failure patients.
  • Measurements included anthropometrics, lipoproteins, apolipoproteins (apoB, apoAI), and high-sensitivity C-reactive protein (hsCRP).
  • Simultaneous analysis of 17 cytokines using bioplex technology.

Main Results:

  • 39% of HF patients had MetS.
  • HF patients with MetS showed higher apoB levels and a lower apoAI/apoB ratio.
  • Elevated plasma IL-8 and serum hsCRP concentrations were observed in HF patients with MetS.

Conclusions:

  • Metabolic syndrome in heart failure patients is associated with a significantly increased degree of inflammation.
  • Findings provide insights into the inflammatory pathways connecting MetS and HF.
  • Inflammation may be a key mechanism underlying the adverse effects of MetS on HF.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...